-
GTA 6 Release Date Confirmed for November 19; Troubleshooting Pre-load and Launch Errors
-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Dolphin Congratulates Shore Fire Media and Its Clients on 20 GRAMMY(R) Nominations, Including 10 Best Album Nods Across Diverse Genres
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Bell Rose Capital (OTCID:BELR) Makes Major Move Into Streaming Entertainment With Spark TV Partnership And New Billy Carson Series "The Missing Chapter"
-
Investments & Wealth Institute Expands Advanced Education Offerings for 2027, Announces Next Experience Conference in Nashville
-
Dermata Announces U.S. Trademark Registration for TOME(R)
-
Olenox October Bitcoin Production Climbs to Three-Month High as Uptime and Hashrate Advance
-
5E Advanced Materials Highlights Commercial Momentum in First Month as an Operating Borates Producer
-
Trout CPA Expands Partner Leadership with Michael Carr and Dan Lerew
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
Jumia Reports Third Quarter 2026 Results
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
What to Do When Two Households Become One
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
TrizCom PR Wins Fourth PRSA Dallas Best of Show Award; Founder Jo Trizila Receives Norm Teich Award
-
Paris Hilton Guides Loti as Chief Advocacy Officer to Put Digital Identity Protection in Everyone's Hands
-
UCLA's Scooter Jackson named Week 11 Lott IMPACT Trophy Player of the Week
-
Oleria Extends Identity Governance to AI Agents, Tracing Every Agent Through the People and Credentials It Acts For
-
Bill Shelow, LIBRA Insurance Partners President and CEO, Receives NAILBA’s 2026 Douglas Mooers Award for Excellence
-
Digital Infrastructure World 2027 Announces First 85 Speakers as Registrants Represent 80GW of AI Buying Capacity
-
Wyyerd Fiber Brings Arizona's Fastest Internet to the City of Phoenix
Novo Nordisk spends big in France to expand obesity drug capacity
Danish pharmaceutical giant Novo Nordisk will announce Thursday a major investment in a French production site to expand capacity for a blockbuster anti-obesity drug, the French presidency said.
In a deal to be sealed officially with President Emmanuel Macron, Novo Nordisk will invest 2.1 billion euros ($2.3 billion) in an existing facility in Chartres, southwest of Paris.
Novo Nordisk is the European Union's most valuable company with market capitalisation of around $460 billion, mostly thanks to growing use of its anti-diabetes drugs as weight-loss derivatives.
The Danish company has found that its Semaglutide medication, originally meant for diabetes, is also effective against obesity, giving it massive global potential.
Marketed as Wegovy in the United States, Denmark, Norway and Germany, the drug helps chronically overweight patients by stimulating insulin secretion and acting as an appetite suppressant.
Goldman Sachs, a financial firm, predicted last month that the global market for anti-obesity medication (AOM) could grow to $100 billion by 2030, against around six billion now.
Obesity rates have almost tripled around the world since 1975, and are set to rise further, it said.
In the United States alone, 15 million adults were likely to receive anti-obesity treatment by 2030, Goldman said, identifying Novo Nordisk, and rivals Eli Lilly, as the world's two dominant AOM makers by then.
Novo Nordisk will double the size of its French site, adding 500 jobs to the 1,600 already there. The investments mostly concern the production of diabetes drugs, cartridges and vials, it said, with a 2028 target date for completion.
Novo Nordisk already said this month it was investing 42 billion Danish kroner ($6.1 billion) to expand its facilities in Denmark.
The French presidency credited Macron's drive to attract foreign industrial investment to France for the Novo deal.
It follows a 6.7-billion-euro ($7.3 billion) pledge for the production and recycling of electric batteries by Asian firms.
An investment of 500 million euros by US pharma company Pfizer was announced in May during a "Choose France" investment conference hosted by Macron.
Stung by recent drugs shortages in France, including for basic antibiotics and pain medicine paracetamol, the government has been keen to bring pharmaceutical production back to the country.
Novo Nordisk said it hopes to win full regulatory approval to sell Wegovy as an anti-obesity drug in France next year.
R.Garcia--AT